2.4.1.219	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20165914/	Supplementing transglucosidase with a high-fiber diet for prevention of postprandial hyperglycemia in streptozotocin-induced diabetic dogs.	therapeutic application	2	
2.4.1.219	Hyperglycemia	https://pubmed.ncbi.nlm.nih.gov/20165914/	Supplementing transglucosidase with a high-fiber diet for prevention of postprandial hyperglycemia in streptozotocin-induced diabetic dogs.	unassigned	-	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	diagnostic usage	1	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	therapeutic application	2	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	ongoing research	3	
2.4.1.219	Diabetes Mellitus	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	unassigned	-	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	diagnostic usage	1	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	therapeutic application	2	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	ongoing research	3	
2.4.1.219	Diabetes Mellitus, Type 2	https://pubmed.ncbi.nlm.nih.gov/22098444/	Effects of transglucosidase on diabetes, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.	unassigned	-